Ibrance® is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer1. Ibrance® has been enlisted as subsidized medical treatment against one specific disease by the Community Care Fund2.
- Ibrance® Prescribing Information. Pfizer Corporation Hong Kong Limited: Version December 2019
- Items Supported by the Samaritan Fund and Community Care Fund Medical Assistance Programme. Hong Kong Hospital Authority. Accessed on 18 March 2021. Available at https://www.ha.org.hk/visitor/ha_visitor_index.asp?content_id=208076#.
Related Release:IBRANCE® (palbociclib) Significantly Reduced the Risk of Disease Progression in Asian Postmenopausal Women with ER+, HER2- Metastatic Breast Cancer